{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-22-007168","form_type":"8-K","ticker":"ODYY","cik":"0001626644","company_name":"Odyssey Health, Inc.","filed_at":"2022-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.484643+00:00","generated_at":"2026-06-22T18:31:59.868259+00:00","sec_items":["8.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Odyssey Health files patent for intranasal brain-drug device; Phase I study successful","bullets":["Filed US/global patent for breath-propelled intranasal brain-drug delivery device (Nasal Device).","Phase I study of PRV-002 concussion drug via Nasal Device completed; well-tolerated in 40 healthy volunteers.","No Nasal Device failures documented; device deposits drug deep into nasal cavity for direct CNS diffusion.","CEO Michael Redmond cited advantage of direct brain delivery with fewer side effects for neurological treatments."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-22-007168","json":"https://secwatch.observer/filing/0001683168-22-007168.json","markdown":"https://secwatch.observer/filing/0001683168-22-007168.md","text":"https://secwatch.observer/filing/0001683168-22-007168.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1626644/000168316822007168/0001683168-22-007168-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1626644/000168316822007168/odyssey_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T18:31:59.868259+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}